GlassScriptPhysician profile
Alexander Geyer
NPI 1083631444
$2,437.12
in general payments reported to CMS, 2019-2025
17 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.45 · 2024: $898 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $668.15 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $314.71 | 2020-2025 | Tezspire, Fasenra, Breztri |
| Verona Pharma, INC. | $245.37 | 2025 | Ohtuvayre |
| Baxter Healthcare | $215.79 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Genzyme Corporation | $202.58 | 2024-2025 | |
| Insmed, INC. | $181.34 | 2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.25 | 2024-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $95.53 | 2024-2025 | Dupixent |
| Viatris Specialty LLC | $72.54 | 2025 | Yupelri |
| Electromed, INC. | $64.48 | 2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $52.98 | 2024-2025 | Acthar |
| Mylan Specialty L.P. | $40.60 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $33.09 | 2024 | |
| Ani Pharmaceuticals, INC. | $23.39 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $21.12 | 2024 | Tezspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $20.84 | 2025 | Nuzyra |
| Actelion Pharmaceuticals US, INC. | $17.36 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Geyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.